Oppenheimer Cuts Target on Derma Sciences (DSCI) to $19
Tweet
Share
E-mailGet Alerts DSCI Hot Sheet
Price: $7.00 --0%
Rating Summary:
1 Buy, 4 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 12 | Down: 23 | New: 22
Rating Summary:
1 Buy, 4 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 12 | Down: 23 | New: 22
Join SI Premium – FREE
Oppenheimer lowered its price target on Derma Sciences (NASDAQ: DSCI) from $21 to $19 following the dilutive capital raise, but kept its Outperform rating.
"We continue to expect DSCI to begin enrollment in a Phase III study of DSC127 in 4Q12 and expect data read-out by YE2014. Importantly, owing to the dilutive nature of this financing," the analyst notes.
For an analyst ratings summary and ratings history on Derma Sciences click here. For more ratings news on Derma Sciences click here.
Shares of Derma Sciences closed at $9.62 yesterday.
"We continue to expect DSCI to begin enrollment in a Phase III study of DSC127 in 4Q12 and expect data read-out by YE2014. Importantly, owing to the dilutive nature of this financing," the analyst notes.
For an analyst ratings summary and ratings history on Derma Sciences click here. For more ratings news on Derma Sciences click here.
Shares of Derma Sciences closed at $9.62 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Freedom Broker Upgrades PrimeEnergy Resource (PNRG) to Hold
- York Space Systems (YSS) PT Lowered to $15 at Jefferies
- Rakus Co Ltd (3923:JP) PT Raised to JPY1,300 at Macquarie
Create E-mail Alert Related Categories
Analyst Comments, Analyst PT ChangeSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
